Early α-synuclein aggregation decreases corticostriatal glutamate drive and synapse density
- PMID: 40250719
- DOI: 10.1016/j.nbd.2025.106918
Early α-synuclein aggregation decreases corticostriatal glutamate drive and synapse density
Abstract
Neuronal inclusions of α-synuclein (α-syn) are pathological hallmarks of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). α-Syn pathology accumulates in cortical neurons which project to the striatum. To understand how α-syn pathology affects cortico-striatal synapses at early time points before significant dopamine neuron loss, pre-formed α-syn fibrils (PFF) were injected into the striatum to induce endogenous α-syn aggregation in corticostriatal-projecting neurons. Electrophysiological recordings of striatal spiny projection neurons (SPNs) from acute slices found a significant decrease in evoked corticostriatal glutamate release and corticostriatal synaptic release sites in mice with PFF-induced aggregates compared to monomer injected mice. Expansion microscopy, confocal microscopy and Imaris reconstructions were used to identify VGLUT1 positive presynaptic terminals juxtaposed to Homer1 positive postsynaptic densities, termed synaptic loci. Quantitation of synaptic loci density revealed an early loss of corticostriatal synapses. Immunoblots of the striatum showed reductions in expression of pre-synaptic proteins VGLUT1, VAMP2 and Snap25, in mice with α-syn aggregates compared to controls. Paradoxically, a small percentage of remaining VGLUT1+ synaptic loci positive for pS129-α-syn aggregates showed enlarged volumes compared to nearby synapses without α-syn aggregates. Our combined physiology and high-resolution imaging data point to an early loss of corticostriatal synapses in mice harboring α-synuclein inclusions, which may contribute to impaired basal ganglia circuitry in PD and DLB.
Keywords: Dementia with Lewy bodies; Glutamatergic; Parkinson's disease; Striatum; Synapses; Α-Synuclein.
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors would like to acknowledge the following agencies and foundations for their generous support of our work: Parkinson Association of Alabama (predoctoral Fellowship to CFB), Parkinson's Disease Foundation (Visiting Scholar Fellowship PF-VSF-1149805 and PF-VSF-944247 to CFB, MSM and LVD), Michael J. Fox Foundation (MJFF-023031 to MSM and LVD), NIH (R01NS132293, R01NS132293-S1, and R00NS110878 to MSM; R01AG081433 to LVD), the Harry T Mangurian Foundation (MSM), and the UF Fixel Institute Pilot Award (MSM). The authors report no competing financial interests or disclosures.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
